SGLT2 Inhibitors and Continuation of Renin Angiotensin Blockade
0:00
21:23
Dr. Briggs and Brendon Neuen discuss his paper in the December issue of JASN. This article on the CREDENCE and EMPA-CKD clinical trials shows that SGLT2 inhibitors allow more consistent use of RAS blockade in patients with declining renal function.
D'autres épisodes de "Journal of the American Society of Nephrology (JASN)"
Ne ratez aucun épisode de “Journal of the American Society of Nephrology (JASN)” et abonnez-vous gratuitement à ce podcast dans l'application GetPodcast.